ROMLUSEVIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 17:29:01 GMT 2023` Edited by `admin` on `Sat Dec 16 17:29:01 GMT 2023`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	SM01RRU9KK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROMLUSEVIMAB

Official Name

English

ROMLUSEVIMAB [USAN]

Common Name

English

BRII-198

Code

English

IMMUNOGLOBULIN G1-LAMBDA2, ANTI-SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV) (SPIKE GLYCOPROTEIN (PEPLOMER PROTEIN)); HOMO SAPIENS MONOCLONAL ANTIBODY; .GAMMA.1 HEAVY CHAIN HOMO SAPIENS (1-448) (VH (HOMO SAPIENS IGHV7-4-1*02 (96%)-(IGHD)-IGHJ

Common Name

English

romlusevimab [INN]

Common Name

English

BRII 198 [WHO-DD]

Common Name

English

IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN,RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONALANTIBODY

Common Name

English

BRII198

Code

English

Code System Code Type Description

FDA UNII

SM01RRU9KK

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

USAN

JK-256

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

INN

11992

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

SMS_ID

300000026355

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

CAS

2509447-08-7

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

NCI_THESAURUS

C175226

Created by admin on Sat Dec 16 17:29:01 GMT 2023 , Edited by admin on Sat Dec 16 17:29:01 GMT 2023

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_146	2_202
2_222	4_213
2_263	2_323
1_146	1_202
2_369	2_427
3_22	3_87
3_136	3_195
4_22	4_87
4_136	4_195
1_222	3_213
1_228	2_228
1_231	2_231
1_263	1_323
1_369	1_427

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_299
N	2_299

Related Record Type Details


					8R39BE7TJJ

SPIKE GLYCOPROTEIN (SARS-COV-2)

TARGET -> INHIBITOR

Comments:

BRII-198 has no or moderately reduced binding activity (approximately two to three-fold) to human Fc receptors (FcR I, FcR IIa, FcR IIb, FcR IIIa.

Interaction Type:

BINDING

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					2AD5KH3SE4

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL